INNMF (Amplia Therapeutics) EV-to-EBITDA : -17.72 (As of Jul. 14, 2025)

Amplia Therapeutics EV-to-EBITDA Chart

Amplia Therapeutics Annual Data
	Trend	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24	Mar25
EV-to-EBITDA		Get a 7-Day Free Trial					-6.32	-4.29	-1.56	-3.03	-2.54

Amplia Therapeutics Semi-Annual Data
	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															-1.56	-	-3.03	-	-2.54

Competitive Comparison of Amplia Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Amplia Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's EV-to-EBITDA falls into.

Amplia Therapeutics EV-to-EBITDA Calculation

Amplia Therapeutics's EV-to-EBITDA for today is calculated as:

Amplia Therapeutics's current Enterprise Value is $74.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics  (OTCPK:INNMF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Amplia Therapeutics's PE Ratio (TTM) for today is calculated as:

Amplia Therapeutics's share price for today is $0.2301.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Amplia Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics Business Description